These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Pharmacokinetics and 48-week safety and efficacy of generic lopinavir/ritonavir in Thai HIV-infected patients. Ramautarsing RA; van der Lugt J; Gorowara M; Sophonphan J; Ananworanich J; Lange JM; Burger DM; Phanuphak P; Ruxthungtham K; Avihingsanon A Antivir Ther; 2013; 18(2):249-52. PubMed ID: 22908131 [TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetics of lopinavir/ritonavir when given with isoniazid in South African HIV-infected individuals. Decloedt EH; van der Walt JS; McIlleron H; Wiesner L; Maartens G Int J Tuberc Lung Dis; 2015 Oct; 19(10):1194-6. PubMed ID: 26459532 [TBL] [Abstract][Full Text] [Related]
10. Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis. Brill MJ; Svensson EM; Pandie M; Maartens G; Karlsson MO Int J Antimicrob Agents; 2017 Feb; 49(2):212-217. PubMed ID: 28038962 [TBL] [Abstract][Full Text] [Related]
12. Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations. Bouazza N; Foissac F; Fauchet F; Burger D; Kiechel JR; Treluyer JM; Capparelli EV; Lallemant M; Urien S Antivir Ther; 2015; 20(2):225-33. PubMed ID: 25279808 [TBL] [Abstract][Full Text] [Related]
13. A pilot, prospective, open-label simplification study to evaluate the safety, efficacy, and pharmacokinetics of once-daily lopinavir-ritonavir monotherapy in HIV-HCV coinfected patients: the MONOCO study. Cooper C; la Porte C; Tossonian H; Sampalis J; Ackad N; Conway B HIV Clin Trials; 2012; 13(4):179-88. PubMed ID: 22849960 [TBL] [Abstract][Full Text] [Related]
14. Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir. Rabie H; Tikiso T; Lee J; Fairlie L; Strehlau R; Bobat R; Liberty A; McIlleron H; Andrieux-Meyer I; Cotton M; Lallemant M; Denti P Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071055 [TBL] [Abstract][Full Text] [Related]
15. Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the ACTG 5283 study. Luque AE; Cohn SE; Park JG; Cramer Y; Weinberg A; Livingston E; Klingman KL; Aweeka F; Watts DH Antimicrob Agents Chemother; 2015 Apr; 59(4):2094-101. PubMed ID: 25624326 [TBL] [Abstract][Full Text] [Related]
16. Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients. van Heeswijk RP; Bourbeau M; Seguin I; Giguere P; Garber GE; Cameron DW Br J Clin Pharmacol; 2005 Apr; 59(4):398-404. PubMed ID: 15801934 [TBL] [Abstract][Full Text] [Related]
17. Concentration-response model of lopinavir/ritonavir in HIV-1-infected pediatric patients. Bouazza N; Urien S; Blanche S; Hirt D; Foissac F; Benaboud S; Tréluyer JM; Frange P Pediatr Infect Dis J; 2014 Aug; 33(8):e213-8. PubMed ID: 24509655 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Timmer CJ; Mulders TM Clin Pharmacokinet; 2000 Sep; 39(3):233-42. PubMed ID: 11020137 [TBL] [Abstract][Full Text] [Related]
19. The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children. Musiime V; Fillekes Q; Kekitiinwa A; Kendall L; Keishanyu R; Namuddu R; Young N; Opilo W; Lallemant M; Walker AS; Burger D; Gibb DM J Acquir Immune Defic Syndr; 2014 Jun; 66(2):148-54. PubMed ID: 24828266 [TBL] [Abstract][Full Text] [Related]
20. Drug monitoring and viral response to lopinavir/ritonavir or saquinavir/ritonavir containing regimens in individuals infected with the human immunodeficiency virus type 1. Falkensammer B; Fasser W; Scherer K; Zemann A; Parson W; Ulmer H; Dierich MP; Stoiber H Int J Immunopathol Pharmacol; 2005; 18(1):145-54. PubMed ID: 15698519 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]